Nitrofurantoin
NDC Package 16571-740-24
Package Information
Nitrofurantoin is oral suspension is indicated in adults and pediatric patients 1 month of age and older for the treatment of urinary tract infections due to susceptible strains of Escherichia coli, Enterococcus species, Staphylococcus aureus, Klebsiella species and Enterobacter species.Limitations of UseNitrofurantoin oral suspension is not indicated for the treatment of pyelonephritis or perinephric abscesses [see Warnings and Precautions (5.7)].UsageTo reduce the development of drug-resistant bacteria and maintain the effectiveness of nitrofurantoin oral suspension and other antibacterial drugs, nitrofurantoin oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. Marketed by Rising Pharma Holdings, Inc., this product is identified by NDC 16571-740 and is authorized under FDA application NDA009175.
Identification & Billing
- RxCUI: 311989 - nitrofurantoin 25 MG in 5 mL Oral Suspension
- RxCUI: 311989 - nitrofurantoin 5 MG/ML Oral Suspension
- RxCUI: 311989 - nitrofurantoin 25 MG per 5 ML Oral Suspension
- RxCUI: 422434 - nitrofurantoin 50 MG in 5 mL Oral Suspension
- RxCUI: 422434 - nitrofurantoin 10 MG/ML Oral Suspension
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 16571 - Rising Pharma Holdings, Inc.
- 16571-740 - Nitrofurantoin
- 16571-740-24 - 1 BOTTLE in 1 CARTON / 230 mL in 1 BOTTLE
- 16571-740 - Nitrofurantoin
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 16571-740-24 identifies a specific commercial package of 1 bottle in 1 carton / 230 ml in 1 bottle of Nitrofurantoin, labeled by Rising Pharma Holdings, Inc.. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Rising Pharma Holdings, Inc. on December 23, 2020. The current certification is valid through May 01, 2025.
How is this Rising Pharma Holdings, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 16571074024. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. There are 230 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.